NICE nod for AbbVie's plaque psoriasis drug

21 August 2019

There was nice news for US biopharma major AbbVie (NYSE: ABBV) today, as the UK health technology appraiser issued a positive guidance for its Skyrizi (risankizumab).

The National Institute for Health and Care Excellence (NICE) today announced that eligible patients in England and Wales with plaque psoriasis who have failed conventional systemic therapies will have access to Skyrizi.

The Technology Appraisal Guidance (TAG) represents the completion of the final step of NICE assessment and follows a positive recommendation by the NICE through its Fast Track Appraisal process, which has an accelerated timeframe of 30 days for implementation rather than the usual 90 days associated with a Single Technology Appraisal.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK